You've just added:

Home / News

Press Releases

October 04, 2023

Aerium Therapeutics Advances Next Generation Antibodies to Protect Immunocompromised Persons Against COVID-19

Monoclonal antibodies could provide a much-needed tool to protect vulnerable populations from severe COVID-19 Continue Reading

October 03, 2023

The Oxford-Harrington Rare Disease Centre Launches Pioneering Therapeutics Accelerator to Advance Innovative Treatments for Rare Diseases

The Therapeutics Accelerator will identify, fund and advance innovative projects from academic partners in the U.K. and U.S. with the goal to deliver 40 new potentially life-changing therapies for rare diseases into clinical trials over 10 years. Continue Reading

September 23, 2023

AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics

Agreement enables the development of therapeutics, including AcuraStem's AS-202 Candidate, an antisense oligonucleotide that suppresses levels of the PIKFYVE kinase Continue Reading

September 14, 2023

AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders

New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC) Continue Reading

July 05, 2023

Takeda Licenses LSU Health New Orleans Technology for Potential Rare Neurological Disorders

New Orleans, LA – LSU Health New Orleans today announced that has exercised its option to receive an exclusive license to certain early-stage technology designed to slow the progression of DNA repeat expansion disorders.In DNA repeat expansion disorders, a segment of repeated DNA expands within a gene to cause disease. The... Continue Reading

May 09, 2023

Nominations Open for 11th Annual International Harrington Prize for Innovation in Medicine

Harrington Discovery Institute and the American Society for Clinical Investigation seek nominations to recognize an outstanding achievement by a physician-scientist Continue Reading

May 01, 2023

Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisis

Atsena Therapeutics announced that the FDA has cleared the company’s IND application for a Phase I/II clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS), featuring Harrington Scholar Shannon Boye, PhD, University of Florida. Continue Reading

April 26, 2023

Harrington Discovery Institute Announces 2023 Scholar-Innovator Award Recipients

10 physician-scientists have been selected for drug development grant to advance discoveries into the clinic Continue Reading

April 10, 2023

Harrington Discovery Institute Opens Call for 2024 Harrington Scholar-Innovator Award

Unique program for physician-scientists to advance promising discoveries into medicines Continue Reading

We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.